Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.
Shailesh AdvaniEdmund S KopetzPublished in: Journal of surgical oncology (2019)
Metastatic colorectal cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard-of-care therapy. To explore the current landscape of clinical trials for mCRC, we reviewed over 600 clinical trials that are currently ongoing for mCRC patients. Immunotherapeutic agents form approximately 39% (includes monoclonal antibodies, viruses, vaccines, and immunomodulators) of all agents and targeted therapy forms 45% (tyrosine kinase inhibitors, epigenetic modulators, and others) of all agents being investigated for mCRC.
Keyphrases
- clinical trial
- metastatic colorectal cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- healthcare
- palliative care
- peritoneal dialysis
- gene expression
- stem cells
- randomized controlled trial
- metabolic syndrome
- small molecule
- mesenchymal stem cells
- single cell
- insulin resistance
- skeletal muscle
- smoking cessation